ADIAL PHARMACEUTICALS INC (ADIL)
US00688A2050 - Common Stock
Taking everything into account, ADIL scores 2 out of 10 in our fundamental rating. ADIL was compared to 198 industry peers in the Pharmaceuticals industry. The financial health of ADIL is average, but there are quite some concerns on its profitability. ADIL has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ADIL has reported negative net income.
In the past year ADIL has reported a negative cash flow from operations.
In the past 5 years ADIL always reported negative net income.
ADIL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -108.10%, ADIL is not doing good in the industry: 84.10% of the companies in the same industry are doing better.
ADIL has a worse Return On Equity (-125.39%) than 65.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -108.1% | ||
| ROE | -125.39% | ||
| ROIC | N/A |
ROA(3y)-196.77%
ROA(5y)-180.1%
ROE(3y)-355.62%
ROE(5y)-292.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ADIL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, ADIL has more shares outstanding
The number of shares outstanding for ADIL has been increased compared to 5 years ago.
There is no outstanding debt for ADIL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -17.83, we must say that ADIL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ADIL (-17.83) is worse than 85.64% of its industry peers.
There is no outstanding debt for ADIL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.83 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 4.90 indicates that ADIL has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.90, ADIL is doing good in the industry, outperforming 64.62% of the companies in the same industry.
ADIL has a Quick Ratio of 4.90. This indicates that ADIL is financially healthy and has no problem in meeting its short term obligations.
ADIL's Quick ratio of 4.90 is fine compared to the rest of the industry. ADIL outperforms 66.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.9 | ||
| Quick Ratio | 4.9 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 66.77% over the past year.
EPS 1Y (TTM)66.77%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q50.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 16.20% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y66.71%
EPS Next 2Y-28.97%
EPS Next 3Y-34.48%
EPS Next 5Y16.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ADIL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADIL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as ADIL's earnings are expected to decrease with -34.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.97%
EPS Next 3Y-34.48%
5. Dividend
5.1 Amount
No dividends for ADIL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADIAL PHARMACEUTICALS INC
NASDAQ:ADIL (5/3/2024, 7:00:00 PM)
After market: 1.7 0 (0%)1.7
-0.09 (-5.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap6.88M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -108.1% | ||
| ROE | -125.39% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.9 | ||
| Quick Ratio | 4.9 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)66.77%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y66.71%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y